

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION

Pr **HEMGENIX**[®]

Etranacogene dezaparvovec

1×10^{13} genome copies/mL, suspension for intravenous infusion

Antihemorrhagic

ATC Code: B02BD16

CSL Behring Canada Inc.
55 Metcalfe Street, Suite 1460
Ottawa, ON K1P 6L5

Date of Initial Authorization:
OCT 23, 2023

Submission Control Number: 273721

RECENT MAJOR LABEL CHANGES

N/A

TABLE OF CONTENTS

Sections or subsections that are not applicable at the time of authorization are not listed.

RECENT MAJOR LABEL CHANGES 1

TABLE OF CONTENTS 2

PART I: HEALTH PROFESSIONAL INFORMATION..... 4

1 INDICATIONS..... 4

 1.1 Pediatrics.....4

 1.2 Geriatrics4

2 CONTRAINDICATIONS 4

4 DOSAGE AND ADMINISTRATION 4

 4.1 Dosing Considerations4

 4.2 Recommended Dose and Dosage Adjustment5

 4.4 Administration.....7

 4.5 Missed Dose12

5 OVERDOSAGE..... 12

6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING 12

7 WARNINGS AND PRECAUTIONS 13

 7.1 Special Populations.....16

 7.1.1 Pregnant Women16

 7.1.2 Breast-feeding16

 7.1.3 Pediatrics16

 7.1.4 Geriatrics16

8 ADVERSE REACTIONS 17

 8.1 Adverse Reaction Overview.....17

 8.2 Clinical Trial Adverse Reactions17

 8.3 Less Common Clinical Trial Adverse Reactions18

 8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other
 Quantitative Data18

 8.5 Post-Market Adverse Reactions18

9	DRUG INTERACTIONS	18
9.2	Drug Interactions Overview	18
9.3	Drug-Behavioural Interactions.....	18
9.4	Drug-Drug Interactions	18
9.5	Drug-Food Interactions.....	19
9.6	Drug-Herb Interactions.....	19
9.7	Drug-Laboratory Test Interactions.....	19
10	CLINICAL PHARMACOLOGY	19
10.1	Mechanism of Action.....	19
10.2	Pharmacodynamics	19
10.3	Pharmacokinetics	21
11	STORAGE, STABILITY AND DISPOSAL	22
12	SPECIAL HANDLING INSTRUCTIONS.....	23
PART II: SCIENTIFIC INFORMATION		24
13	PHARMACEUTICAL INFORMATION	24
14	CLINICAL TRIALS	24
14.1	Clinical Trials by Indication	24
15	MICROBIOLOGY	27
16	NON-CLINICAL TOXICOLOGY	27
PATIENT MEDICATION INFORMATION.....		28

PART I: HEALTH PROFESSIONAL INFORMATION

1 INDICATIONS

HEMGENIX (etranacogene dezaparvovec) is indicated for treatment of adults (aged 18 years of age or older) with Hemophilia B (congenital Factor IX deficiency) who require routine prophylaxis to prevent or reduce the frequency of bleeding episodes.

There is no clinical experience of HEMGENIX use in patients with mild or moderate Hemophilia B (FIX activity > 2%).

1.1 Pediatrics

The safety and efficacy of HEMGENIX in children below 18 years of age has not been studied. No data are available.

1.2 Geriatrics

Out of 54 total patients, the Phase 3 clinical study with HEMGENIX (CT-AMT-061-02) included 6 patients who were over 65 years of age at time of enrollment. There were no differences in the safety and efficacy of HEMGENIX in these patients compared to younger patients although the comparisons are limited by small numbers.

2 CONTRAINDICATIONS

HEMGENIX is contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container.

For a complete listing, see 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING.

4 DOSAGE AND ADMINISTRATION

4.1 Dosing Considerations

HEMGENIX must be prescribed and administered by a health professional experienced in treating Hemophilia.

Patient selection

For patient selection, baseline testing is required. This includes examinations of:

- Preexisting neutralizing AAV5 antibody titer (See 7 WARNINGS AND PRECAUTIONS). A patient blood sample is required for testing for AAV5 neutralizing antibodies. If a patient has AAV5 neutralizing antibodies above a pre-determined threshold they will not be eligible for treatment with HEMGENIX. If a patient has no detectable AAV5 neutralizing antibodies or neutralizing antibodies below the established threshold then the patient may be eligible for treatment with HEMGENIX.
- Factor IX inhibitor presence. In case of a positive test for alloantibodies against Factor IX, a re-test within approximately 2 weeks should be performed. If both the initial test and re-test results are positive, the patient should not receive HEMGENIX.

- Liver health, including:
 - Enzyme testing (alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and total bilirubin). It is recommended that the ALT test is repeated at least once prior to HEMGENIX administration to establish patient’s ALT baseline.
 - Hepatic ultrasound and elastography.

In case of radiological liver abnormalities and/or sustained liver enzyme elevations, consideration of a consultation with hepatologist is recommended to assess eligibility for HEMGENIX noting that patients with severe hepatic impairment or active liver infections were excluded from clinical studies with HEMGENIX (See 7 WARNINGS AND PRECAUTIONS).

4.2 Recommended Dose and Dosage Adjustment

HEMGENIX must be administered intravenously as a single dose of 2×10^{13} genome copies (gc) per kilogram (kg) of body weight (bw) after dilution with 0.9% sodium chloride solution (normal saline) (See 4.4 Administration).

The dose should be calculated as follows:

HEMGENIX dose (in mL) = *The per kilogram dose of 2×10^{13} gc/kg multiplied by body weight (in kg) divided by the concentration of HEMGENIX at 1×10^{13} gc/mL.*

Number of HEMGENIX vials needed = HEMGENIX dose (in mL) divided by 10 (round up to next whole number of vials).

The division factor 10 represents the extractable volume of HEMGENIX from each vial (10 mL).

The total volume of the patient’s HEMGENIX dose to be diluted may be less than the total volume of vials needed.

Table 1. Number of HEMGENIX vials required by patient body weight

Total Number of Vials	Patient Body Weight (kg)	Total Volume (mL)
10	46-50	100
11	51-55	110
12	56-60	120
13	61-65	130
14	66-70	140
15	71-75	150
16	76-80	160
17	81-85	170
18	86-90	180
19	91-95	190
20	96-100	200
21	101-105	210
22	106-110	220
23	111-115	230

Total Number of Vials	Patient Body Weight (kg)	Total Volume (mL)
24	116-120	240
25	121-125	250
26	126-130	260
27	131-135	270
28	136-140	280
29	141-145	290
30	146-150	300
31	151-155	310
32	156-160	320
33	161-165	330
34	166-170	340
35	171-175	350
36	176-180	360
37	181-185	370
38	186-190	380
39	191-195	390
40	196-200	400
41	201-205	410
42	206-210	420
43	211-215	430
44	216-220	440
45	221-225	450
46	226-230	460
47	231-235	470
48	236-240	480

Special Populations

Pediatric population

The safety and efficacy of HEMGENIX in children below 18 years of age has not been studied. No data are available. Health Canada has not authorized an indication for pediatric use (See 1.1 Pediatrics).

Women

HEMGENIX is not intended for administration in women.

Geriatric population

Clinical studies with HEMGENIX included 6 elderly patients with Hemophilia B aged 68 to 75 years at time of enrollment. While limited by small numbers, there were no meaningful differences in the safety and efficacy of HEMGENIX in these patients compared to patients aged 18 to 65 years and no dose adjustment should be considered.

Renal impairment

In the pivotal Phase 3 study, 8 of the 54 enrolled patients were renally impaired. Seven patients had mild and 1 patient had moderate renal impairment (See 14

CLINICAL TRIALS). All 8 patients with renal impairment responded to HEMGENIX treatment. No dose adjustment should be considered.

Patients with severe renal impairment and end-stage renal disease were excluded from clinical studies and the safety and efficacy of HEMGENIX in these patients has not been established. (See 10.3 Pharmacokinetics).

Hepatic impairment

The safety and efficacy of HEMGENIX in patients with advanced hepatic impairment, including cirrhosis, advanced liver fibrosis (e.g. suggestive of or equal to METAVIR [Meta-analysis of Histological Data in Viral Hepatitis] Stage 3 disease or a liver elastography [FibroScan score of ≥ 9 kPa], or uncontrolled Hepatitis B and C, has not been established (See 10.3 Pharmacokinetics). No dose adjustments are recommended for patients with hepatic disorders should they be considered eligible for treatment with HEMGENIX (See 7 WARNINGS AND PRECAUTIONS).

4.4 Administration

- **HEMGENIX is administered only once.**
- For single-dose intravenous infusion only.
- Use HEMGENIX vial(s) only once.

General Instructions

- Follow universal biohazard precautions for handling. For instructions on preparation, handling, measures to take in case of accidental exposure to and disposal of the medicinal product, see 11 SPECIAL HANDLING INSTRUCTIONS.
- HEMGENIX does not contain preservatives. Use aseptic techniques during the preparation and administration of HEMGENIX. Use a new needle/vial adapter and syringe for each HEMGENIX vial.
- DO NOT expose HEMGENIX to the light of an ultraviolet radiation disinfection lamp.
- Confirm that the patient's identity matches with the patient-specific identifier number on the outer carton.
- Verify the required dose of HEMGENIX based on the patient's body weight. The total number of vials in each finished pack corresponds to the dosing requirement for each individual patient based on the body weight (See **Table 1**).
- Confirm that the carton contains sufficient number of vials to prepare the diluted HEMGENIX patient-specific infusion bag.
- In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products, except for 0.9% normal saline solution used HEMGENIX dilution prior to administration. The compatibility of HEMGENIX was established for intravenous infusion lines with integrated in-line 0.2 μm filters made out of polyethersulfone (PES).
- After dilution, HEMGENIX should be a clear, colourless solution.

For instructions on dilution of the product before administration, see below (Section *Preparation*).

PREPARATION

Required supplies and materials for product preparation (not included in product package)

- Normal saline infusion bag(s)* of 500 mL (1 or 2 based on the patient’s body weight – see *Step 1: Product Preparation*)
- Label(s)** for the infusion bag(s) of 500 mL
- IV Infusion line*/drip chamber* primed with 0.9% normal saline
- Infusion bag connector(s)
- 20 mL or larger luer-lock syringe(s)*
- 20 G needles* or vial adaptors*
- 70% isopropyl alcohol
- Sharps disposal container

Table 2 shows the supplies and materials compatible with HEMGENIX.

Table 2: Supplies and Materials Compatible with HEMGENIX (Preparation)

Component*	Material of Construction
Normal saline infusion bag (0.9% normal saline)	PE/PP copolymer (PVC free)
IV Infusion line/drip chamber	PVC/TOTM, PP/styrene-ethylene-butylene-styrene
Luer-lock syringe	PP, Silicone
20 G Needle	Stainless Steel
Vial adaptor	PP, Silicone; PP, stainless; MABS, acrylic silicone; ABS

ABS = Acrylonitrile butadiene styrene MABS = Methyl methacrylate acrylonitrile butadiene styrene; PE = Polyethylene; PP = Polypropylene; PVC = Polyvinyl Chloride; TOTM = Trioctyltrimellitate

** Information to be included on the infusion bag label:

- Product name: Diluted HEMGENIX
- Patient identifier
- Expiration date/time (24h from the vial removal from refrigerator)
- Storage condition: Room temperature (15-25°C) protected from light
- Contains recombinant viral vector product
- Number of infusion bags (e.g., 1 of 2 bags / 2 of 2 bags, or 1 of 1 bag).

Step 1: Product Preparation

- a. HEMGENIX must be diluted with 0.9% normal saline solution prior to administration.
 - Prior to dilution, withdraw the volume of the calculated HEMGENIX dose (in mL) from the 500 mL infusion bag(s) with 0.9% normal saline solution. The volume of 0.9% normal saline to be removed from the infusion bag(s) will vary based on the patient body weight.
 - For patients <120 kg bw, dilute HEMGENIX in one 500 mL-0.9% normal saline solution infusion bag.

- For patients ≥ 120 kg bw, dilute HEMGENIX with two 500 mL-0.9% normal saline solution infusion bags by dividing the total dose of HEMGENIX equally between two 500 mL infusion bags.

Table 3: Required Number of Infusion Bags and Respective Volume

Patient body weight	Number of 500 mL 0.9% normal saline infusion bag(s) required	Volume of 0.9% normal saline to withdraw
Less than 120 kg body weight	1	Equal to the total HEMGENIX dose (in mL) from one bag
Equal to or more than 120 kg body weight	2	Equal to the total HEMGENIX dose (in mL). Remove half of the dose equivalent volume from each of the two infusion bags.

- Remove the amount of 0.9% normal saline with a luer lock syringe at the mixing adapter site of the applicable connector.

Step 2: Addition of HEMGENIX to the infusion bags

- Add the volume of the required HEMGENIX dose to the infusion bag(s) to bring the total volume in each infusion bag back to 500 mL.
- DO NOT** add HEMGENIX into the airspace of the infusion bag during diluting.
- Gently invert the infusion bag(s) at least 3 times to mix the solution and ensure even distribution of the diluted product.
- To avoid foaming:
 - **DO NOT** shake the HEMGENIX vial(s) or the prepared infusion bag(s).
 - **DO NOT** use filter needles during preparation of HEMGENIX.
- To reduce the risk of spillage and/or aerosol formation, the infusion bag(s) should be connected to an infusion tubing prefilled with sterile 0.9% normal saline solution.
- The infusion tubing prefilled with sterile 0.9% normal saline solution should be connected to the main intravenous infusion line which has been primed with sterile 0.9% normal saline solution prior to use.

ADMINISTRATION

Required supplies and materials for infusion (not included with the product package)

- Winged intravenous needle* or catheter set*
- Infusion pump
- 0.2 μm in-line filter*
- Antiseptic skin preps
- 70% isopropyl alcohol wipes
- Gauze and tape, or transparent dressing
- Sharps disposal container
- Virucidal agent to treat spill/spill kit

Table 4 shows the supplies and materials compatible for infusion of HEMGENIX.

Table 4: Supplies and Materials Compatible for Infusion of HEMGENIX (Administration)

Component*	Material of Construction
Winged intravenous needle or catheter set	PVC/TOTM, MABS
0.2 µm In-line filter	PES
Catheter	PVC/DEHT, stainless steel

DEHT = Di(2-ethylhexyl)terephthalate MABS = Methyl methacrylate acrylonitrile butadiene styrene; PES = Polyether sulfone; PVC = Polyvinyl chloride; TOTM = Trioctyltrimellitate

Infusion rate

The diluted product should be administered at a constant infusion rate of 500 mL/hour (8 mL/min).

HEMGENIX **MUST NOT** be administered as an intravenous push or bolus.

- In the event of an infusion reaction during administration, the infusion rate should be slowed or stopped to ensure patient tolerability (see 7 WARNINGS AND PRECAUTIONS). If the infusion is stopped, it may be restarted at a slower rate when the infusion reaction is resolved and based on patient tolerability (e.g. 250mL/hour, which should take approx. 2 hours for administration).
- If the infusion rate needs to be reduced, or stopped and restarted, the HEMGENIX solution should be infused within the shelf life of diluted HEMGENIX, i.e., within 24 hours after the dose preparation.

Step 3: Infusion of HEMGENIX

- a. **DO NOT** infuse the diluted HEMGENIX solution in the same intravenous line with any other products.
- b. **DO NOT** use a central line or port.
- c. Diluted HEMGENIX should be visually inspected prior to administration. The diluted HEMGENIX should be a clear, colourless solution.
- d. **DO NOT** use HEMGENIX if particulates, cloudiness or discoloration are visible in the infusion bag, do not use HEMGENIX.
- e. Use the product after dilution as soon as possible. You **MUST NOT** exceed the storage time of the diluted product beyond that provided in 11 STORAGE, STABILITY AND DISPOSAL.
- f. Use an integrated (in-line) 0.2 µm filter made out of polyethersulfone (PES).
- g. The diluted HEMGENIX solution must be administered into a peripheral vein by a separate intravenous infusion line through a peripheral venous catheter.

- h. HEMGENIX solution should be infused closely following the infusion rate(s) provided above. The administration should be completed within ≤ 24 hours after the dose preparation.
- i. After the entire content of the infusion bag(s) is infused, the infusion line must be flushed at the same infusion rate with 0.9% normal saline solution to ensure all HEMGENIX is delivered.
- j. Treat spills of HEMGENIX with a virucidal agent with proven activity against non-enveloped viruses.

Monitoring post-infusion

After administration of HEMGENIX, regular monitoring is required. This includes examinations of:

- Liver enzymes to monitor for liver enzyme elevations which may indicate immune-mediated liver hepatotoxicity (See 7 WARNINGS AND PRECAUTIONS). Monitor ALT levels by testing weekly for at least 3 months following administration of HEMGENIX. After 3 months, it is recommended to test ALT every 3 months in the first year post-treatment and every 6 months in the second year post-treatment, with subsequent yearly testing for at least 5 years to routinely assess liver function.
- Factor IX activity (e.g. weekly for at least 3 months).
 - Monitor patients regularly for their Factor IX activity (see 7 WARNINGS and PRECAUTIONS, Monitoring and Laboratory Tests).
 - Use of exogenous Factor IX concentrates before and after HEMGENIX administration may affect an accurate estimation of HEMGENIX-derived Factor IX activity.
- Perform regular alpha-fetoprotein (AFP) level testing and abdominal ultrasound (e.g. annually) in patients with preexisting risk factors for hepatocellular carcinoma (See 7 WARNINGS AND PRECAUTIONS).
- Monitor patients for human Factor IX inhibitors. Post-dose testing should be performed if plasma Factor IX activity levels are not achieved, decrease or if bleeding is not controlled or returns.

Corticosteroid regimen

An immune response to the AAV5 capsid proteins will occur after HEMGENIX administration (See 8 ADVERSE REACTIONS). This may lead to elevations in liver transaminases (transaminitis) (See 7 WARNINGS AND PRECAUTIONS and 8 ADVERSE REACTIONS). In case of elevated ALT levels above the normal limits or to double of the patient's baseline value within the first 3 months post-dose, a corticosteroid treatment should be considered to dampen the immune response, e.g. starting with oral 60 mg/day prednisolone or prednisone (see

Table 5). Corticosteroid tapering should be commenced, once the ALT levels are below the upper limit of normal levels.

Table 5: Recommended prednisolone treatment applied in clinical studies with HEMGENIX

Timeline	[§] Prednisolone oral dose (mg/day)
Week 1	60
Week 2	40
Week 3	30
Week 4	30
Maintenance dose until ALT level returns to baseline level	20
Taper dose after baseline level has been reached	Reduce daily dose by 5 mg/week

[§]Medications equivalent to prednisolone may also be used. A combined immunosuppressant regimen or the use of other products can also be considered in case of prednisolone treatment failure or contraindication.

Discontinuation of continuous routine prophylaxis with exogenous human Factor IX

It may take several weeks before improved hemostatic control becomes apparent after HEMGENIX infusion (See 10.3 Pharmacokinetics). Therefore, continued hemostatic support with exogenous human Factor IX may be required during the first weeks after HEMGENIX administration to provide sufficient Factor IX coverage for the initial days post-treatment. Monitoring of the Factor IX activity (e.g. weekly for at least 3 months) is recommended post-dose to follow patient's response to HEMGENIX.

4.5 Missed Dose

HEMGENIX is administered only once.

5 OVERDOSAGE

There are no clinical study data regarding overdose with HEMGENIX.

For management of a suspected drug overdose, contact your regional poison control centre.

6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING

To help ensure the traceability of biologic products, including biosimilars, health professionals should recognise the importance of recording both the brand name and the non-proprietary (active ingredient) name as well as other product-specific identifiers such as the Drug Identification Number (DIN) and the batch/lot number of the product supplied.

Table 6. Dosage Forms, Strengths, Composition and Packaging

Route of Administration	Dosage Form / Strength/Composition	Non-medicinal Ingredients
Intravenous	1×10^{13} genome copies (gc)/mL; suspension for intravenous infusion	Disodium phosphate, Hydrochloric acid (<i>for pH adjustment</i>), Polysorbate-20, Potassium chloride, Potassium dihydrogen phosphate, Sodium chloride, Sucrose, Water for Injection

- HEMGENIX is a clear, colourless solution stored in a glass vial.
- After dilution with sterile 0.9% normal saline, HEMGENIX should be a clear, colourless solution.
- Each mL of HEMGENIX contains a nominal concentration of 1×10^{13} genome copies (gc).
- Each vial contains an extractable volume of not less than 10 mL of suspension for intravenous infusion.
- The total number of vials in each pack corresponds to the dosing requirement for the individual patient, depending on the patient's body weight, and is provided on the package (refer to **Table 1**).

7 WARNINGS AND PRECAUTIONS

General

Shedding

Shedding of HEMGENIX vector DNA will occur in blood, feces and semen of patients receiving HEMGENIX. Since some patients have detectable viral/transgene DNA detected in semen between 1 to 2 years following administration of HEMGENIX, barrier contraception is recommended for 2 years for males and their female partners of childbearing potential (see Reproductive Health: Female and Male potential).

Blood, organ, and tissue donation

Patients treated with HEMGENIX should not donate blood, or organs, tissues and cells for transplantation to minimize the risk of exposure to non-target individuals. Caregivers should be advised on the proper handling of waste material generated from contaminated medicinal ancillaries during HEMGENIX use (see 12 SPECIAL HANDLING INSTRUCTIONS).

Driving and Operating Machinery

Patients treated with HEMGENIX may experience dizziness, fatigue, headaches, chest tightness and abdominal pain shortly after administration of HEMGENIX that may affect their ability to drive and use machines. Patients should not drive or use machines until symptoms resolve.

Hematologic

Risk of Thromboembolic Events

In clinical studies with HEMGENIX, treatment-related thromboembolic events were not reported and there was no evidence of supraphysiological FIX activity occurring in any patient.

Restoration of Factor IX activity following administration of HEMGENIX, which encodes for a hyperactive Factor IX variant (Padua), may give rise to the potential risk for thromboembolic events. This potential risk is increased in Hemophilia B patients with pre-existing risk factors for thromboembolic events such as a history of cardiovascular disease, arteriosclerosis, hypertension, diabetes, and advanced age.

Hepatic/Biliary/Pancreatic

Hepatotoxicity

Hemophilia B patients with ALT, AST, total bilirubin and ALP > 2X upper limit of normal (ULN), advanced liver fibrosis (e.g. suggestive of or equal to METAVIR [Meta-analysis of Histological Data in Viral Hepatitis] Stage 3 disease or a liver elastography [FibroScan score of ≥ 9 kPa]), or uncontrolled Hepatitis B or C were excluded from clinical studies with HEMGENIX. There should be careful consideration before administering HEMGENIX to these patients.

Intravenous administration of a liver-directed AAV vector may potentially lead to liver transaminase elevations (transaminitis). Transaminitis, particularly when observed in the first 3 months after HEMGENIX administration, is presumed to occur due to immune-mediated injury of transduced hepatocytes and may reduce the therapeutic efficacy of the AAV-vector based gene therapy.

In clinical studies with HEMGENIX, transient, asymptomatic and predominantly mild elevations in liver transaminases were observed, most often in the first 3 months after HEMGENIX administration. Some transaminase elevations resolved spontaneously while others required administration of a corticosteroid taper to normal levels after a period of up to several weeks. Patients requiring treatment with corticosteroids following administration of HEMGENIX had numerically lower transgene FIX activity compared to patients who were not treated with corticosteroids (see 11 PHARMACOLOGY).

To mitigate the risk of potential hepatotoxicity, transaminases should be closely monitored at least once per week for at least 3 months after HEMGENIX administration. A course of corticosteroid taper should be considered in the event of ALT increase to above the upper limit of normal or to double the patient's baseline levels, along with human Factor IX activity examinations (See 4.4 Administration).

Follow-up monitoring of transaminases in all patients who developed liver enzyme elevations is recommended on a regular basis until liver enzymes return to baseline.

It is recommended to advise patients treated with HEMGENIX to avoid, if possible, concomitant use of hepatotoxic medication or potential hepatotoxic agents (including potentially hepatotoxic herbal products, nutritional supplements, and alcohol) due to the risk of potential loss or decrease in efficacy and more serious hepatic reactions.

Hepatocellular carcinogenicity

HEMGENIX is composed of a non-replicating AAV5 vector whose DNA remains largely in episomal form although DNA integration events have been reported in non-clinical (see 16 NON-CLINICAL TOXICOLOGY) and clinical studies. Vector integration into human genome, expected to occur at low frequency, may potentially result in insertional mutagenesis that could contribute to the development of malignancies. HEMGENIX-associated clonal expansion or carcinogenicity was not observed in preclinical or clinical studies. One patient with pre-existing risk factors for developing hepatic cancer developed a hepatocellular carcinoma following treatment with HEMGENIX, which was assessed as not likely related to the gene therapy based on vector integration site analyses and whole genome sequencing (where vector DNA was estimated to be integrated in < 0.03% of tumour cells).

It is recommended that patients with pre-existing risk factors for hepatocellular carcinoma (such as hepatic cirrhosis, advanced hepatic fibrosis, hepatitis C or B disease, non-alcoholic fatty liver disease) receive regular abdominal ultrasound screenings and are regularly monitored (e.g. annually) for alpha-fetoprotein (AFP) elevations in the 5 years following administration (See 4.4 Administration).

Immune

Immune-mediated neutralization of the AAV5 vector capsid

In AAV-vector based gene therapies, pre-existing neutralizing AAV antibodies may impede transgene expression at desired therapeutic levels.

In the clinical studies with HEMGENIX, patients were not excluded based on pre-existing AAV5 neutralizing antibodies and the patient sub-group with detectable pre-existing neutralizing AAV5 antibodies had a mean Factor IX activity that was lower compared to that patient sub-group without detectable pre-existing neutralizing AAV5 antibodies. However, both patient groups, with and without detectable pre-existing neutralizing AAV5 antibodies, demonstrated an improved hemostatic protection compared to the standard of care Factor IX prophylaxis, except for one patient with a very high pre-existing neutralizing AAV5 titer who had no Factor IX transgene activity and was required to resume prophylactic treatment with exogenous Factor IX. Based on information obtained from the Phase 3 CT-AMT-061-02 clinical study, a threshold for an acceptable AAV5 neutralizing titer has been established to screen patients for eligibility to receive HEMGENIX (see 4 DOSAGE AND ADMINISTRATION).

Infusion-related reactions

Serious infusion related reactions, including hypersensitivity reactions and anaphylaxis, can occur during and immediately following HEMGENIX administration. Symptoms may include chest tightness, headaches, abdominal pain, light-headedness, flu-like symptoms, shivering, flushing, rash, and hypertension. Closely monitor patients for signs or symptoms of infusion reactions throughout the infusion period and for at least 3 hours after end of infusion. In the event of an infusion reaction during administration, the infusion may be slowed or stopped. If the infusion is stopped, restart at a slower rate when the infusion reaction has resolved. Consider treatment with a corticosteroid or antihistamine for management of an infusion reaction.

In clinical studies with HEMGENIX in adult patients, three individuals had their infusions temporarily interrupted and resumed at a slower infusion rate. One individual who had their infusion stopped due to a serious hypersensitivity reaction did not resume treatment and had no measurable response to therapy.

Monitoring and Laboratory Tests

After HEMGENIX administration, a patient's Factor IX activity should be regularly monitored.

The activated partial thromboplastin time (aPTT)-based one-stage clotting assay (OSA) may produce variable results between laboratories for determining Factor IX activity and this can be affected by the type of aPTT reagent, laboratory, equipment and the reference standard used in the assay. This is important when considering changing the laboratory, equipment and/or reagents used in the assay.

Therefore, the same assay, laboratory, equipment and reagents are recommended to be used to monitor each patient's Factor IX activity over time.

The results of Factor IX activity tests are lower if measured with the two-stage chromogenic substrate assay (CSA) compared to the aPTT one-stage assay. In the clinical efficacy study with HEMGENIX, the post-dose Factor IX activity measured with CSA gave results that were approximately 50% lower (the mean CSA to aPTT one-stage Factor IX activity ratio ranging from 0.41 to 0.55).

Monitor patients through appropriate clinical observations and laboratory tests for the development of inhibitors to Factor IX after HEMGENIX administration. Perform an assay that detects Factor IX inhibitors if bleeding is not controlled, or plasma Factor IX activity levels decrease. If Factor IX activity decreases in the absence of FIX inhibitors, then loss of transgene expression in the liver should be suspected.

Reproductive Health: Female and Male Potential

- **Fertility**

No clinical studies have been performed to evaluate the effects of HEMGENIX on impairment of human fertility. Vector DNA in some hemophilia B patients has been detected up to 2 years following infusion of HEMGENIX, clinical significance is unknown. It is recommended that male hemophilia B patients and their female partners of childbearing potential use barrier contraception for 2 years following infusion of HEMGENIX.

7.1 Special Populations

7.1.1 Pregnant Women

HEMGENIX is not intended for administration in women and no women were enrolled in clinical studies with HEMGENIX.

7.1.2 Breast-feeding

HEMGENIX is not intended for administration in women and no women were enrolled in clinical studies with HEMGENIX.

7.1.3 Pediatrics

Pediatrics (<18 years): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use.

7.1.4 Geriatrics

See Section 1.2 Geriatrics.

8 ADVERSE REACTIONS

8.1 Adverse Reaction Overview

The safety of HEMGENIX was evaluated in two clinical studies (the first study enrolled 3 patients and the Phase 3 CT-AMT-061-02 study enrolled 54 patients). Both studies enrolled adult male Hemophilia B patients with moderately severe or severe disease (N = 57), and who received a single intravenous dose of 2×10^{13} gc/kg body weight of HEMGENIX.

The most frequently reported adverse drug reactions in clinical studies related to HEMGENIX were ALT elevations (10/57 patients [17.5%]), headache (9/57 patients [15.8%]), influenza-like illness (8/57 patients [14%]) and AST elevations (5/57 patients [8.8%]). For all Treatment Emergent Adverse Events (TEAEs) please refer to **Table 7**.

The most common adverse reactions were infusion-related reactions [19/57 patients (33%)], including serious events (see WARNINGS and PRECAUTIONS, Immune).

8.2 Clinical Trial Adverse Reactions

Clinical trials are conducted under very specific conditions. The adverse reaction rates observed in the clinical trials; therefore, may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse reaction information from clinical trials may be useful in identifying and approximating rates of adverse drug reactions in real-world use.

Table 7: Treatment Emergent Adverse Events $\geq 5\%$ Following Treatment With HEMGENIX

MedDRA System Organ Class (SOC) Treatment Emergent Adverse Events	HEMGENIX N = 57 n (%)
Gastrointestinal disorders	
Nausea	6 (10.5%)
General disorders and administration site conditions	
Fatigue	14 (24.5%)
Influenza-like illness	8 (14.0%)
Malaise	5 (8.8%)
Investigations	
Alanine aminotransferase increased	12 (21.0%)
Aspartate aminotransferase increased	9 (15.8%)
Blood creatine phosphokinase increased	9 (15.80%)
Injury, poisoning and procedural complications	
Infusion-related reactions ^a	19 (33.0%)
Nervous system disorders	
Headache	18 (31.6%)

^a Infusion-related reaction: In 7 patients symptoms occurred during infusion, in 12 patients after infusion. Symptoms occurring in $\geq 5\%$ of patients were: Dizziness, Flu-like symptoms and Headache. Symptoms occurring in $< 5\%$ of patients were: Abdominal pain, Abdominal discomfort, Chest discomfort, Chills, Eye pruritus, Fever (Pyrexia), Flushing, Hives (Urticaria), Infusion site reaction, and Tachycardia. Eleven patients recovered on the day or day one after infusion. Eight patients recovered within 8 days after infusion.

8.3 Less Common Clinical Trial Adverse Reactions

- Investigations: Blood bilirubin increased: [(1/57, 1.8%)]
- Nervous system disorders: Dizziness: [(2/57 patients, 3.5%)]

8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data

Table 8 describes hepatic laboratory abnormalities following administration of HEMGENIX. ALT increases are further characterised, as they may be accompanied by decreased Factor IX activity and may indicate the need to initiate corticosteroid treatment.

Table 8: Hepatic laboratory abnormalities in patients administered 2×10^{13} gc/kg body weight HEMGENIX in clinical studies

Laboratory Parameter Increases ^a	HEMGENIX N = 57 n (%)
ALT increases > ULN^b	23 (40.4%)
> ULN – 3.0 x ULN ^c	17 (29.8%)
> 3.0 – 5.0 x ULN ^d	1 (1.8%)
> 5.0 – 20.0 x ULN ^e	1 (1.8%)
AST increases > ULN^b	24 (42.1%)
> ULN – 3.0 x ULN ^c	19 (33.3%)
> 3.0 – 5.0 x ULN ^d	4 (7.0%)
Bilirubin increases > ULN^b	14 (24.6%)
> ULN – 1.5 x ULN ^c	12 (21.1%)

Abbreviations: ULN = Upper Limit of Normal; CTCAE = Common Terminology Criteria for Adverse Events

^aHighest post-dose CTCAE Grades of values are presented

^bNot all patients with laboratory abnormality >ULN reached CTCAE Grade 1 due to elevated baseline levels

^cCTCAE Grade 1

^dCTCAE Grade 2

^eCTCAE Grade 3

8.5 Post-Market Adverse Reactions

Not Applicable

9 DRUG INTERACTIONS

9.2 Drug Interactions Overview

No drug interactions have been established.

9.3 Drug-Behavioural Interactions

Interactions with behavioural risks have not been established.

9.4 Drug-Drug Interactions

No interaction studies have been performed.

9.5 Drug-Food Interactions

Interactions with food have not been established.

9.6 Drug-Herb Interactions

Interactions with herbal products have not been established.

9.7 Drug-Laboratory Test Interactions

Interactions with laboratory tests have not been established.

10 CLINICAL PHARMACOLOGY

10.1 Mechanism of Action

HEMGENIX is a gene therapy designed to introduce a copy of the human Factor IX gene into hepatocytes to address the root cause of the Hemophilia B disease. HEMGENIX consists of a codon-optimized coding DNA sequence of the gain-of-function Padua variant of the human Factor IX (hFIXco-Padua), under control of the liver-specific LP1 promoter, encapsulated in a non-replicating recombinant adeno-associated viral vector of serotype 5 (AAV5).

Following single intravenous infusion, HEMGENIX enter cells of the body, where the vector DNA resides almost exclusively in episomal form. After transduction, HEMGENIX directs liver-specific expression of Factor IX-Padua protein using a liver specific promoter (LP1). As a result, HEMGENIX helps to restore circulating Factor IX procoagulant activity of Hemophilia B patients and their hemostatic potential, which limits bleeding episodes and the need for exogenous Factor IX treatment.

10.2 Pharmacodynamics

Factor IX activity

The mean Factor IX activity levels over time, as measured by one-stage [activated Partial Thromboplastin Time (aPTT)-based] assay are summarized in

Table 9. Patients achieved a mean (\pm SD) uncontaminated (i.e., excluding measurements within five half-lives of Factor IX replacement therapy) Factor IX activity levels of 39% (\pm 18.7), 41.5% (\pm 21.7), 36.9% (\pm 21.4) and 36.7 (\pm 19.0) of normal, respectively, at 6, 12, 18 and 24 months. The time to onset of Factor IX protein expression post-dose was detectable by first uncontaminated measurement at Week 3 in the clinical efficacy study (N = 54).

Table 9. Summary of Uncontaminated Factor IX Activity Over Time Following Administration of 2×10^{13} gc/kg of HEMGENIX [FAS; One-Stage (aPTT-Based) Assay]

Factor IX Activity in % (One-stage)			
	Patient Number (*n)	Median (Min, Max)	Mean (SD)
Week 3	43	23.7 (4.9, 56.7)	26.8 (12.7)
Month 3	51	33.8 (7.6, 91.0)	36.8 (18.2)
Month 6	51	37.3 (8.2, 97.1)	39.0 (18.7)
Month 12	50	39.9 (5.9, 113.0)	41.5 (21.7)
Month 18	50	33.6 (4.5, 122.9)	36.9 (21.4)
Month 24	50	33.9 (4.7, 99.2)	36.7 (19.0)

Study: Hope B trial

Abbreviations: SD = Standard Deviation; FAS = Full Analysis Set including all 54 patients dosed; Min = Minimum; Max = Maximum. Uncontaminated Factor IX activity values exclude measurements within five half-lives of Factor IX replacement therapy. *Contaminated and missing values are not shown here. Specifically, the number of patients excluded for contamination with Factor IX replacement therapy at Week 3, Month 3, Month 6, Month 12, Month 18, and Month 24, were 10, 3, 3, 3, 3, 2, respectively.

Hemophilia B patients treated with HEMGENIX and who received corticosteroids due to liver enzyme elevations had numerically lower Factor IX activity compared to Hemophilia B patients treated with HEMGENIX and who did not require corticosteroids [see section Warning and Precaution, *Hepatotoxicity*]. Factor IX activity in these patients at month 6 following infusion of HEMGENIX are shown (**Table 10**).

Table 10: Uncontaminated Factor IX Activity at Month 6 in Hemophilia B Patients Treated with and Without Corticosteroids

Statistic	Factor IX Activity in % (One-stage aPTT Assay)	
	Without Corticosteroids	With Corticosteroids
n	46	9
Mean (SD)	42.8 (17.4)	18.7 (11.1)
Median (Q1, Q3)	37.7 (32.7, 51.4)	15.9 (10.0, 25.1)

Special Populations and Conditions

- Pediatrics**

HEMGENIX has not been studied in children below 18 years of age. No data are available.

- Geriatrics**

Limited data (N = 7) from 60 -75 years subgroup showed that the mean Factor IX activity levels were approximately up to 2-fold higher in this subgroup compared to 18 to < 40 years of age subgroup (N = 31), but comparable to 40 to <60 years age subgroup (N = 15).

- **Hepatic Impairment**

In the Phase 3 study, patients with varying degree of baseline liver steatosis, specifically the degree of hepatic steatosis with the Controlled Attenuation Parameter (CAP) score of $\geq S2$ (≥ 260 decibels/m) versus $< S2$ (< 260 decibels/m) were compared. Patients with (CAP) scores of $\geq S2$ (≥ 260 decibels/m; n=12; range: 262 to 400), $< S2$ (< 260 decibels/m; n=28; range: 100 to 259) and missing score (n=14) showed no clinically relevant difference in Factor IX activity levels between the groups following HEMGENIX administration.

Patients with advanced liver impairment and advanced fibrosis (elastography of e.g. ≥ 9 kPA, or suggestive of or equal to METAVIR Stage 3 disease) were excluded from clinical studies.

- **Renal Impairment**

In the Phase 3 study, patients with mild renal impairment [creatinine clearance (CLcr) = 60 to 89 mL/min defined by Cockcroft-Gault equation, n=7] were observed to have numerically higher Factor IX activity (up to 37% relative difference) compared to those with normal renal function (CLcr ≥ 90 mL/min; n=45) across different time points following HEMGENIX administration. One patient with moderate renal impairment (CLcr = 30 to 59 mL/min) in this study had similar Factor IX activity as patients with normal renal function.

HEMGENIX was not studied in patients with severe renal impairment (CLcr = 15 to 29 mL/min) or end-stage renal disease (CLcr < 15 mL/min).

10.3 Pharmacokinetics

HEMGENIX vector DNA shedding

Temporary shedding of HEMGENIX vector DNA occurred in blood and semen of patients receiving HEMGENIX. Although the vector DNA remains largely episomal, integration of viral DNA in non-clinical and clinical studies have been reported and the risks of an adverse effect to human health although low are possible (see 7 WARNINGS AND PRECAUTIONS).

The pharmacokinetics of vector DNA shedding in blood and semen following HEMGENIX administration was characterized in clinical studies with 57 Hemophilia B patients.

The pharmacokinetics of shedding following HEMGENIX administration was characterised using a sensitive polymerase chain reaction (PCR) assay to detect vector DNA sequences in blood and semen samples. This assay is sensitive to transgene DNA, including fragments of degraded DNA. It does not indicate whether DNA is present in the vector capsid, in cells or in the fluid phase of the matrix (e.g., blood plasma, seminal fluid), or whether intact vector is present.

In the Phase 2b study (N=3), clearance of vector DNA from semen and blood, as confirmed by 3 subsequent measurements below limit of detection (LOD), was achieved in 2/3 patients after 3 years post-dose. One of 3 patients had positive blood testing results at 30 months post-dose and did not return the required number of semen samples to assess the shedding status as per the definition of 3 subsequent measurements below the LOD.

In the Phase 3 study, the time of observed maximum levels of vector DNA ranged between 4 to 7 hours in blood and between weeks 5 and 27 in semen after HEMGENIX administration (N=54 patients). The earliest absence of vector DNA in blood (i.e., confirmed with 3 subsequent measurements below LOD of vector DNA) was observed by week 17 (1/54; 1.9% of patients). A total of 56% (30/54) of patients reached absence of vector DNA from blood by month 24. The earliest absence of vector DNA in semen was observed by week 6 (1/54; 1.9% of patients). A total of 69% (37/54) of patients reached absence of vector DNA from semen by month 24. Several patients did not return the required number of blood and semen samples to assess the shedding status as per the definition. Considering shedding results obtained from the final 2 available consecutive samples, a total of 40/54 (74%) and 47/54 (87%) patients were identified to have reached absence of vector DNA from blood and semen, respectively, at 24 months post-dose. The median time to absence of vector DNA in semen was 52.3 weeks in blood and 45.8 weeks in semen at 24 months post-dose.

11 STORAGE, STABILITY AND DISPOSAL

- HEMGENIX is shipped at +2°C to +8°C.
- Upon receipt, store HEMGENIX vials in a refrigerator at +2°C to +8°C.
- DO NOT FREEZE.
- Store HEMGENIX in the original package in order to protect from light, until time of dilution and administration
- The shelf life of HEMGENIX is 24 months from the date of manufacture.

Stability after dilution

Once diluted with 0.9% normal saline (see 4.4 Administration), HEMGENIX can be stored at +15 to +25°C in the infusion bag protected from light. However, the administration of HEMGENIX dose to the patient should be completed within 24 hours after the dose preparation.

The stability after dilution was established for Polyethylene/Polypropylene (PE/PP) copolymer, Polyvinyl chloride (PVC)-free infusion bags with 0.9% normal saline.

Disposal

HEMGENIX is a recombinant adeno-associated virus. Unused medicinal product and all materials (solid and liquid waste) that have been in contact with the recombinant viral vector product should be handled and disposed of as potentially infectious waste in a container dedicated to biohazard material, autoclaved and destroyed in accordance with local biosafety guidelines.

Non-disposable materials should be cleaned with a disinfectant with proven virucidal activity for non-enveloped viruses e.g. a chlorine releasing disinfectant like hypochlorite containing 0.1% available chlorine (1000 ppm) after usage and then autoclaved, if possible. Contact surfaces should be disinfected with a similar disinfectant.

12 SPECIAL HANDLING INSTRUCTIONS

Personal protective equipment, including gloves, safety goggles, protective clothing and masks, should be worn while handling and administering HEMGENIX.

Measures to take in case of accidental exposure

Accidental exposure to HEMGENIX should be avoided.

Local guidelines on handling of material that have been in contact with the recombinant viral vector product should be followed in case of accidental exposure. Work surfaces and materials which have potentially been in contact with HEMGENIX must be decontaminated with appropriate disinfectant.

- In case of accidental exposure to eyes, immediately flush eyes with water for at least 15 minutes. **DO NOT** use alcohol solution.
- In case of accidental needle stick exposure, encourage bleeding of the wound and wash injection area well with soap and water.
- In case of accidental exposure to skin, the affected area must be thoroughly cleaned with soap and water for at least 15 minutes. **DO NOT** use alcohol solution.
- In case of accidental inhalation, move the person into fresh air.
- In case of accidental oral exposure, abundantly rinse mouth with water.
- In each case, obtain subsequently medical attention.

PART II: SCIENTIFIC INFORMATION

13 PHARMACEUTICAL INFORMATION

Drug Substance

Proper name: Etranacogene dezaparvovec

Chemical name: AAV5-hFIXco-Padua

Structural formula:



AP = activation peptide; FIX = factor IX; hFIXco = human factor IX, codon-optimized; kb = kilobases; LP1 = liver-specific promoter-1; polyA = polyadenylation; PP = pre-pro-peptide; SV40 = simian virus 40.

Physicochemical properties: Clear, colourless solution.

Product Characteristics:

HEMGENIX is a gene therapy medicinal product that employs a non-replicating, recombinant adeno-associated viral vector serotype 5 (AAV5) containing a codon-optimized coding DNA sequence for the human coagulation Factor IX variant R338L (hFIXco-Padua) under the control of a liver-specific promoter (LP1).

HEMGENIX is produced using recombinant baculovirus technology.

14 CLINICAL TRIALS

14.1 Clinical Trials by Indication

Adult Hemophilia B Patients without FIX Inhibitors

Trial Design and Study Demographics

Table 11: Summary of patient demographics for clinical trials in Hemophilia B

Study #	Study design	Dosage, route of administration and duration	Study patients (n)	Median age at enrolment (Range)	Sex
Phase 3 (CT-AMT-061-02)	Open-label, single-dose, single-arm	Single IV dose of 2×10^{13} gc/kg bw	54	37.0 (19-75)	Male

The safety and efficacy of HEMGENIX was evaluated in a prospective, open-label, single-dose, single-arm multi-national study (CT-AMT-061-02). In the ongoing study, fifty-four Hemophilia B patients aged 19 to 75 at enrollment with moderately severe or severe disease completed a ≥ 6 -month observational lead-in period with standard of care routine Factor IX prophylaxis after which patients received a single intravenous dose of HEMGENIX. Post-treatment follow-up visits occurred regularly, with 53/54 patients completing at least 18 months of follow-up. One patient, with numerous cardiovascular and urologic risk factors, aged 75 at screening, died of urosepsis and cardiogenic shock at month 15 post-dose (at age 77 years), an event confirmed not treatment-related. The remaining 53/54 patients will continue on follow-up for a total of 5 years. Of these, 1 patient received a partial dose (10%) of HEMGENIX due to an infusion related hypersensitivity reaction.

Patients were excluded from the study if they were less than 18 years of age, had FIX inhibitors, presented with hepatic or renal dysfunction ($> 2 \times$ ULN in either ALT, AST, total bilirubin, ALP, or creatinine), had HIV not controlled with anti-viral therapy, had a Hepatitis B or C infection, had thrombocytopenia (platelets $< 50 \times 10^9/L$), an active infection, or a medical condition expected to interfere with liver transduction of the vector (i.e. disseminated intravascular coagulation, accelerated fibrinolysis, or advance liver fibrosis).

Study Results

The primary objective was to establish the non-inferiority of HEMGENIX by comparing patient annualized bleeding rates (ABRs) during months 7 to 18 post HEMGENIX treatment (after establishment of stable Factor IX expression by month 6 following HEMGENIX infusion) to the ABR reported in the observational lead-in period of ≥ 6 months treated with prophylactic Factor IX. For this purpose, all bleeding episodes, regardless of investigator assessment, were considered. The results for the total bleeding events are shown in

Table 12 . Non-inferiority of HEMGENIX treatment was demonstrated as the upper bound for the 95% confidence interval of the ABR ratio (post-HEMGENIX treatment/lead-in prophylaxis treatment) is lower than the pre-specified non-inferiority margin of 1.8. For the bleeding episodes that needed Factor-IX treatment during the HEMGENIX treatment period, lower bleeding rates were demonstrated as compared to prophylaxis Factor-IX lead-in period treatment including treated joint and spontaneous bleeds and the results are shown in **Table 13**.

Table 12: Total bleeding events and ABRs

Number	≥6-month Lead-in period (N=54)	7-18 months Post-HEMGENIX (N=54)
Patients with bleeds	40 (74.1%)	20 (37.0%)
Patients with zero bleeds	14 (25.9%)	34 (63.0%)
All bleeds	136	54
Mean adjusted ^{a, b} ABR ^c (95% CI)	4.13 (2.95, 5.22)	1.73 (0.64, 4.02)
ABR ^c ratio (post-dose / lead-in) 2-sided 95% CI	0.42 (0.18, 0.97)	

Abbreviations: ABR = annualized bleeding rate; CI = confidence interval

^aAdjusted: Adjusted ABR and non-inferiority comparison of ABR between lead-in and post-treatment period was estimated using a repeated measures generalized estimating equations negative binomial regression model accounting for the paired design of the study with an offset parameter to account for the differential collection periods. Treatment period was included as a categorical covariate.

^b Two patients contributed to very short person-time (PT) post-treatment as they were not able to stop routine prophylaxis after HEMGENIX treatment during Months 7 to 18. To account for the unstable individual ABRs (due to very short at risk on-treatment PT) for these 2 patients, the post-treatment bleeding counts for these patients were multiply imputed using a negative binomial distribution under conservative assumption of mean ABR of 20 (equivalent to bleeding counts during on-demand treatment) with larger dispersion parameter of 0.74 to reflect higher variability in bleeding counts under on-demand treatment.

^cThe ABR was measured from month 7 to 18 after HEMGENIX infusion, ensuring this period represented steady-state Factor IX expression from the transgene.

Table 13: Treated ABRs and Overall Joint and Spontaneous Bleed Incidences

	≥6-Month Lead-in period (N=54)	7-18 Months Post-HEMGENIX (N=54)
Mean adjusted ^{a, b} ABR (95% CI) based on Factor IX-treated bleeds	3.57 (2.60, 4.54)	1.27 (0.33, 2.98)
ABR ratio ^c (Post-dose/ Lead-in) 2-sided 95% CI for Factor IX-treated bleeds	0.36 (0.11, 0.82)	
Observed Joint Bleed Count (% of total bleeds)	77 (57%)	19 (35%)
Observed Spontaneous Bleed Count (% of total bleeds)	50 (37%)	14 (26%)

Abbreviations: ABR = Annualized Bleeding Rate; CI = Confidence Interval

^aAdjusted: Adjusted ABR and non-inferiority comparison of ABR between lead-in and post-treatment period was estimated using a repeated measures generalized estimating equations negative binomial regression model accounting for the paired design of the study with an offset parameter to account for the differential collection periods. Treatment period was included as a categorical covariate.

^b Two patients contributed to very short person-time (PT) post-treatment as they were not able to stop routine prophylaxis after HEMGENIX treatment during Months 7 to 18. To account for the unstable individual ABRs (due to very short at risk on-treatment PT) for these two patients, the post-treatment bleeding counts for these patients were multiply imputed using negative a binomial distribution under conservative assumption of mean ABR of 20 (equivalent to bleeding counts during on-demand treatment) with larger dispersion parameter of 0.26 to reflect higher variability in bleeding counts under on-demand treatment.

^cThe ABR was measured from month 7 to 18 after HEMGENIX infusion, ensuring this period represented steady-state Factor IX expression from the transgene.

15 MICROBIOLOGY

No microbiological information is required for this drug product.

16 NON-CLINICAL TOXICOLOGY

General Toxicology: Preclinical studies were initiated with a gene therapy product employing the recombinant adeno-associated virus serotype 5 (rAAV5) expressing the wild type human coagulation factor IX (rAAV5-hFIX). HEMGENIX (rAAV5co-hFIX-Padua) was subsequently developed from rAAV5-hFIX by introduction of a 2 nucleotide change in the transgene for human Factor IX, generating the naturally occurring Padua variant of Factor IX, which exhibits significantly augmented activity.

HEMGENIX and its predecessor were intravenously administered to mice and nonhuman primates (NHP) to determine the biodistribution and potential toxicity. Dose-dependent preferential distribution to the liver was confirmed for both vectors and their transgene expression. Both products were well tolerated and not associated with adverse effects during a 3 or 6-month follow up period, respectively. The No Observed-Adverse-Effect-Level (NOAEL) was set at the highest dose tested in NHPs of 9×10^{13} gc/kg bw, which is approximately 5-fold above the recommended human HEMGENIX dose of 2×10^{13} gc/kg bw.

One out of 10 healthy mice administered 5×10^{13} gc/kg of HEMGENIX and the predecessor of HEMGENIX developed pulmonary thrombi at 13 weeks post-dose. This dose level is 2.5-fold higher than the recommended dose level for HEMGENIX. In a non-human primate (NHP) follow-up study, pulmonary thrombi events were not observed at a dose level of 9×10^{13} gc/kg, which is 4.5-fold higher than the recommended dose for HEMGENIX. However, compared to concurrent controls, prolonged prothrombin time, decreased activated partial thromboplastin time and decreased heart rates were observed in the NHPs administered 9×10^{13} gc/kg of HEMGENIX during the 26-week study.

Carcinogenesis and mutagenesis: No dedicated carcinogenicity or mutagenicity studies were conducted with HEMGENIX.

Genotoxicity: Genotoxic and reproductive risks were evaluated with the rAAV5-hFIX. The integration site analysis in host genomic DNA was performed on liver tissue from mice and NHP injected with rAAV5-hFIX up to a dose of 2.3×10^{14} gc/kg bw, corresponding to approximately 10-fold the clinical dose in human. Low level of integrated rAAV5-hFIX DNA was distributed throughout the host genome with no preferred integration in genes associated with mediation of malignant transformation in human.

Reproductive and Developmental Toxicology: The risk of germline transmission after administration of 2.3×10^{14} gc/kg bw rAAV5-hFIX, i.e., a dose approximately 10-fold higher than recommended for human, was assessed in mice. The rAAV5-hFIX administration resulted in detectable vector DNA in the reproductive organs and sperm of male animals. However, following mating of these mice with naïve female animals at 6 days after administration, the rAAV5-hFIX vector DNA was not detected in the female reproductive tissues nor in the resulting foetuses, indicating low risk of paternal germline transmission.

PATIENT MEDICATION INFORMATION

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

HEMGENIX®

Etranacogene dezaparvovec

Read this carefully before you receive **HEMGENIX**. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about **HEMGENIX**.

What is HEMGENIX used for?

People with Hemophilia B are born with a defect in a gene and they do not make enough of a protein known as Factor IX. This protein is important for blood to clot and stop any bleeding. People with Hemophilia B will become sick due to bleeding without treatment. HEMGENIX is given to help make enough working Factor IX protein to stop bleeding in patients with Hemophilia B.

How does HEMGENIX work?

The active substance in HEMGENIX is based on a virus that does not cause disease in humans. This virus cannot spread in the body but can deliver a copy of the Factor IX gene into cells of the body. This allows the body to produce the Factor IX protein and raise the levels of working Factor IX in the blood. This treatment is known as a gene therapy and the Factor IX protein made will help the blood to clot more normally and prevent or reduce bleeding episodes in patients with Hemophilia B.

What are the ingredients in HEMGENIX?

Medicinal ingredients: Etranacogene dezaparvovec.

Non-medicinal ingredients: Disodium phosphate, Hydrochloric acid (for pH adjustment), Polysorbate-20, Potassium chloride, Potassium dihydrogen phosphate, Sodium chloride, Sucrose, Water for injection

This medicine contains recombinant adeno-associated viral vectors.

HEMGENIX comes in the following dosage forms:

Each HEMGENIX vial contains 1×10^{13} gene copies (gc)/mL of etranacogene dezaparvovec.

HEMGENIX is a suspension for intravenous infusion.

HEMGENIX is a clear, colourless solution. After dilution, HEMGENIX is a clear, colourless solution.

Do not use this medicine if you notice particles, cloudiness or discolouration.

Do not use HEMGENIX if:

You are allergic to etranacogene dezaparvovec or to any of the other ingredients of this medicine. If the above applies to you, or if you are unsure of the above, please talk to your healthcare professional before you receive HEMGENIX.

To help avoid side effects and ensure proper use, talk to your healthcare professional before you receive HEMGENIX. Talk about any health conditions or problems you may have, including if you:

- Have an infection
- Have or had liver or kidney problems
- Are planning on having children

For your personal safety, the treatment with HEMGENIX will take place under the supervision of your healthcare professional in a clinical setting.

Before treatment with HEMGENIX

Your healthcare professional will perform several tests **before** you are given HEMGENIX treatment.

- **Antibody blood tests:** Your healthcare professional will conduct blood tests to check for certain antibodies (proteins) before treatment with HEMGENIX, including:
 - Blood tests to check for the amount of antibodies in your blood directed against the type of virus used to make HEMGENIX. If you have too many of these antibodies you will not receive HEMGENIX.
 - Blood tests to check for the presence of antibodies in your blood directed against the human Factor IX protein (Factor IX inhibitors). If you test positive for these antibodies, another test will be performed in approximately 2 weeks. If both the initial test and re-test results are positive, you will not receive HEMGENIX.
- **Liver health:** If you have poor liver health you may not receive HEMGENIX. Your healthcare professional will check the status of your liver health before you start treatment with HEMGENIX and perform:
 - Blood tests to check the level of liver enzymes in your blood
 - Liver ultrasound
 - Tests to check for scarring or thickening of your liver (elastography testing).

During or shortly after HEMGENIX infusion

Your healthcare professional will monitor you **during or shortly after** HEMGENIX infusion.

- **Infusion-related reactions:** Infusion-related side effects can occur during or shortly after you are given the HEMGENIX infusion (drip). Your healthcare professional will monitor you during HEMGENIX infusion and for at least 3 hours after you are given HEMGENIX.
 - Symptoms of such side effects are listed in section “What are possible side effects from using HEMGENIX?”. Tell your healthcare professional or nurse immediately if you experience these or any other symptoms during or shortly after the infusion.
 - Depending on your symptoms, your infusion may be slowed down or interrupted. If the infusion is interrupted, it can be restarted at a slower rate when the infusion reaction is resolved. Your healthcare professional may also consider if you should be given another medicine (corticosteroids) to help manage the infusion reaction.

After treatment with HEMGENIX

After treatment with HEMGENIX, your healthcare professional will continue to check your health. It is **important** that you **discuss the schedule for these blood tests** with your healthcare professional so that they can be carried out as necessary.

- **Liver enzymes:** HEMGENIX will trigger a response within your immune system that could lead to an increased level of certain liver enzymes in your blood called transaminases (transaminitis). Your healthcare professional will regularly monitor your liver enzyme levels to ensure that the medicine is working as it should:
 - In the first 3 months you will have blood tests once per week to monitor your liver enzyme levels.
 - If you experience an increase in liver enzymes, you may have more frequent blood tests to check the levels of your liver enzymes, until they return to normal. You may also need to take another medicine (corticosteroids) to manage these side effects.
 - Your healthcare professional may also perform additional tests to exclude other causes for the increase in your liver enzymes, if needed, in consultation with a healthcare professional experienced in liver diseases (hepatologist).
 - Your healthcare professional will repeat liver enzyme testing tests every three months from month 4 up to one year after you are given HEMGENIX to continue checking of your liver health. In the second year after you are given HEMGENIX, your healthcare professional will follow up your liver enzymes half-yearly. After the second year, your healthcare professional will check your liver enzymes annually for at least 5 years after you are given HEMGENIX.
- **Factor IX levels:** Your healthcare professional will regularly check your Factor IX levels to see if treatment with HEMGENIX was successful.
 - In at least the first 3 months after you are given HEMGENIX, you will have blood tests once per week to check your Factor IX levels.

Discontinuation of other Hemophilia B treatments

After HEMGENIX use, talk to your healthcare professional about if or when you should stop your other Hemophilia B treatments and develop a treatment plan of what to do in case of surgery, trauma, bleeds, or any procedures that will increase your risk of bleeding. It is important to continue your monitoring and **keep your** healthcare professional visits. Discuss if you need to take other medicines to manage your Hemophilia B or any side effects of treatment you may have.

Risk of liver cancer (hepatocellular carcinogenicity)

- HEMGENIX will insert into cells in your body and it could possibly insert into your DNA. This could contribute to a risk of cancer, such as liver cancer. Although this has yet to be reported, this remains possible because of the nature of the medicine. You should therefore discuss this with your physician.
- If you are a patient with risk factors for liver cancer (you have liver cirrhosis or scarring and thickening of the liver, or Hepatitis B, Hepatitis C, or fatty liver), your healthcare professional will monitor your liver health yearly for at least 5 years after HEMGENIX administration and perform the following tests:
 - Annual liver ultrasound and
 - Annual blood tests to check for increases in protein (alpha-fetoprotein).

Avoiding blood donations and donations for transplantations

To ensure HEMGENIX DNA is not transferred from you to another person, you will not be able to donate blood, organs, tissues, or cells after you have been treated with HEMGENIX.

Other warnings you should know about:

- Children and adolescents: HEMGENIX is not recommended for children or adolescents under the age of 18.
- Pregnancy, breast-feeding and fertility: HEMGENIX is not intended for use in women and there are no data regarding HEMGENIX in pregnant or breast-feeding women.
- Driving and using machines: Some side effects of HEMGENIX may affect your ability to drive or use machines. You should wait until the side effects go away before you drive or use machine.
- Shedding and Contraception:
 - The active substance in HEMGENIX may be excreted through your blood, semen, and other bodily waste, a process called shedding.
 - It is recommended that you and your female partner use appropriate barrier contraception for 2 years from treatment to prevent HEMGENIX DNA to be transferred to offspring.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

- Interactions between HEMGENIX and other drugs, vitamins, minerals, natural supplements or alternative medicines have not been established.

How to take HEMGENIX:

- HEMGENIX will be given to you in a hospital setting under direction of a healthcare professional experienced and trained in the treatment of Hemophilia.
- HEMGENIX will be given to you **only once** by a single slow infusion (drip) into a vein after dilution with 0.9% sodium chloride solution (normal saline).
- There will be **no dose** adjustments allowed for medical conditions.
- If you have any questions on the use of HEMGENIX ask your healthcare professional.

Usual dose:

Your healthcare professional will work out the correct dose for you, based on your body weight.

The dose is 2×10^{13} genome copies, the unit the HEMGENIX dose is measured, per kg of your body weight.

Overdose:

There are no clinical study data regarding overdose with HEMGENIX.

If you think you, or a person you are caring for, have taken too much HEMGENIX, contact a healthcare professional, hospital emergency department, or regional poison control centre immediately, even if there are no symptoms.

Missed Dose:

HEMGENIX is administered only once.

What are possible side effects from using HEMGENIX?

Like all medicines, this medicine can cause side effects, although not everybody gets them.

These are not all the possible side effects you may have when taking HEMGENIX. If you experience any side effects not listed here, tell your healthcare professional.

The following side effects were observed in clinical studies with HEMGENIX:

Very Common (may occur with more than 1 in 10 patients)

- Tiredness (Fatigue)
- Headache
- Flu-like illness (Influenza-like illness)
- Increased levels of liver enzymes in the blood (Alanine aminotransferase and Aspartate aminotransferase)
- Increased blood levels of creatine phosphokinase, an enzyme (protein) found mainly in the heart, brain and skeletal muscle
- Infusion related reaction (Hypersensitivity, Infusion site reaction, Dizziness, Eye pruritus, Flushing, Abdominal pain upper, Urticaria (Hives), Chest discomfort, Pyrexia (Fever))

Common (may occur with up to 1 in 100 patients)

- Dizziness
- Feeling sick (Nausea)
- Feeling generally unwell (Malaise)
- Increased blood levels of bilirubin (a yellow breakdown substance of red blood cells that is not being removed well by the liver)

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
VERY COMMON			
Infusion Related Reactions , including fever, low blood pressure, chills, fast heartbeat, difficulty breathing, headache, dizziness, reddening of skin (flushing), abdominal pain, hives, chest discomfort.		√	
Reporting Side Effects			
<p>You can report any suspected side effects associated with the use of health products to Health Canada by:</p> <ul style="list-style-type: none"> • Visiting the Web page on Adverse Reaction Reporting (https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada.html) for information on how to report online, by mail or by fax; or • Calling toll-free at 1-866-234-2345. <p><i>NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.</i></p>			

We recommend that CSL Behring Canada be copied when reporting suspected side effects, at the following address:

AdverseReporting@CSLBehring.com

Storage:

As this medicine will be given in a clinical setting, the clinical personal is responsible for the correct storage of the medicine before and during its use, as well as for its correct disposal. The following information is intended for health professionals only.

- Keep out of reach and sight of children.
- Store in a refrigerator (2 to 8°C). Do not freeze.
- Store vials in the original package in order to protect from light.
- Once diluted with sodium chloride 9 mg/mL (0.9%) solution for injection, HEMGENIX can be stored at 15 °C - 25 °C in the infusion bag protected from light for up to 24 hours after the dose preparation.
- Do not use this medicine after the expiry date which is stated on the vial label and carton after EXP.

Contents of the package

HEMGENIX is supplied in vials containing 10 mL of etranacogene dezaparvovec.

The total number of vials in a pack corresponds to the dosing requirement for individual patient depending on his body weight and is provided on the package.

If you want more information about HEMGENIX:

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website: <https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>; the manufacturer's website <https://www.cslbehring.ca/> or by calling 1-866-773-7721.

This leaflet was prepared by CSL Behring Canada Inc.

Last Revised OCT 23, 2023